Birgitte Volck, MD, PhD is, by 1 June 2016, Head of R&D, Rare diseases at GSK. From 2012-2016 she was Chief Medical Officer and head of Development, leading Sobi’s portfolio of products and product candidates in rare diseases and speciality areas across hemophilia, inflammation, neonatology and genetics. Furthermore, Birgitte held senior positions with Amgen, including Therapeutic Area Head, International R&D for Bone and Inflammation. In addition, Birgitte held various senior medical affairs & R&D positions at Genzyme and Pharmexa. She has published a number of abstracts and papers on biochemical markers in arthritis, and is external lecturer at Copenhagen University.